Needham & Company LLC reaffirmed their hold rating on shares of Omeros (NASDAQ:OMER) in a research note issued to investors on Wednesday, AnalystRatings.com reports.
A number of other equities analysts also recently commented on OMER. BidaskClub downgraded Omeros from a sell rating to a strong sell rating in a report on Saturday, October 12th. HC Wainwright restated a buy rating and set a $35.00 target price on shares of Omeros in a report on Tuesday, November 5th. Maxim Group set a $32.00 target price on Omeros and gave the company a buy rating in a report on Friday, August 9th. Wedbush restated a hold rating and set a $18.00 target price on shares of Omeros in a report on Monday, October 28th. Finally, ValuEngine downgraded Omeros from a buy rating to a hold rating in a report on Wednesday, October 2nd. Three analysts have rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. Omeros has a consensus rating of Hold and an average price target of $25.60.
OMER traded down $0.61 during midday trading on Wednesday, hitting $13.20. The stock had a trading volume of 525,200 shares, compared to its average volume of 478,581. The company has a market cap of $687.02 million, a P/E ratio of -5.95 and a beta of 2.78. The business has a fifty day moving average of $15.37 and a 200 day moving average of $16.90. Omeros has a 1 year low of $10.30 and a 1 year high of $20.92.
In other Omeros news, Director Thomas J. Cable sold 5,000 shares of the stock in a transaction on Monday, October 14th. The stock was sold at an average price of $15.12, for a total value of $75,600.00. Following the completion of the transaction, the director now owns 35,067 shares in the company, valued at $530,213.04. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 12.80% of the stock is currently owned by corporate insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of OMER. Nuveen Asset Management LLC bought a new position in Omeros in the second quarter worth $3,221,000. Chicago Equity Partners LLC bought a new position in Omeros in the second quarter worth $1,094,000. Ingalls & Snyder LLC raised its holdings in Omeros by 1.2% in the third quarter. Ingalls & Snyder LLC now owns 5,023,755 shares of the biopharmaceutical company’s stock worth $82,038,000 after purchasing an additional 58,198 shares in the last quarter. Virtus ETF Advisers LLC bought a new position in shares of Omeros during the second quarter valued at $784,000. Finally, SG Americas Securities LLC increased its holdings in shares of Omeros by 61.0% during the third quarter. SG Americas Securities LLC now owns 130,823 shares of the biopharmaceutical company’s stock valued at $2,136,000 after acquiring an additional 49,548 shares in the last quarter. Institutional investors and hedge funds own 53.46% of the company’s stock.
Omeros Company Profile
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
Featured Story: What is the formula for calculating total return?
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.